177 related articles for article (PubMed ID: 9207432)
1. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance.
Villunger A; Egle A; Marschitz I; Kos M; Böck G; Ludwig H; Geley S; Kofler R; Greil R
Blood; 1997 Jul; 90(1):12-20. PubMed ID: 9207432
[TBL] [Abstract][Full Text] [Related]
2. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
3. Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.
Tinhofer I; Marschitz I; Kos M; Henn T; Egle A; Villunger A; Greil R
Blood; 1998 Jun; 91(11):4273-81. PubMed ID: 9596676
[TBL] [Abstract][Full Text] [Related]
4. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells.
Villunger A; Egle A; Kos M; Hartmann BL; Geley S; Kofler R; Greil R
Cancer Res; 1997 Aug; 57(16):3331-4. PubMed ID: 9269989
[TBL] [Abstract][Full Text] [Related]
5. Fas/Fas ligand (FasL)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells.
Frassanito MA; Silvestris F; Silvestris N; Cafforio P; Camarda G; Iodice G; Dammacco F
Clin Exp Immunol; 1998 Nov; 114(2):179-88. PubMed ID: 9822274
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand.
von Bernstorff W; Spanjaard RA; Chan AK; Lockhart DC; Sadanaga N; Wood I; Peiper M; Goedegebuure PS; Eberlein TJ
Surgery; 1999 Jan; 125(1):73-84. PubMed ID: 9889801
[TBL] [Abstract][Full Text] [Related]
7. Membrane-bound Fas (Apo-1/CD95) ligand on leukemic cells: A mechanism of tumor immune escape in leukemia patients.
Buzyn A; Petit F; Ostankovitch M; Figueiredo S; Varet B; Guillet JG; Ameisen JC; Estaquier J
Blood; 1999 Nov; 94(9):3135-40. PubMed ID: 10556200
[TBL] [Abstract][Full Text] [Related]
8. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
Hahne M; Rimoldi D; Schröter M; Romero P; Schreier M; French LE; Schneider P; Bornand T; Fontana A; Lienard D; Cerottini J; Tschopp J
Science; 1996 Nov; 274(5291):1363-6. PubMed ID: 8910274
[TBL] [Abstract][Full Text] [Related]
9. Co-expression of Fas (APO-1, CD95)/Fas ligand by BeWo and NJG choriocarcinoma cell lines.
Rajashekhar G; Loganath A; Roy AC; Mongelli JM
Gynecol Oncol; 2003 Oct; 91(1):101-11. PubMed ID: 14529668
[TBL] [Abstract][Full Text] [Related]
10. Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: correlation with the prognostic factors.
Kim YS; Kim KH; Choi JA; Lee JH; Kim HK; Won NH; Kim I
Arch Pathol Lab Med; 2000 May; 124(5):687-93. PubMed ID: 10782148
[TBL] [Abstract][Full Text] [Related]
11. Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas.
Peduto Eberl L; Guillou L; Saraga E; Schröter M; French LE; Tschopp J; Juillerat-Jeanneret L
Int J Cancer; 1999 May; 81(5):772-8. PubMed ID: 10328232
[TBL] [Abstract][Full Text] [Related]
12. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo.
Rensing-Ehl A; Frei K; Flury R; Matiba B; Mariani SM; Weller M; Aebischer P; Krammer PH; Fontana A
Eur J Immunol; 1995 Aug; 25(8):2253-8. PubMed ID: 7545115
[TBL] [Abstract][Full Text] [Related]
13. Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC.
Hoves S; Krause SW; Halbritter D; Zhang HG; Mountz JD; Schölmerich J; Fleck M
J Immunol; 2003 Jun; 170(11):5406-13. PubMed ID: 12759415
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo malignant glioma cells are sensitive to Fas (CD95/APO-1) ligand-mediated apoptosis.
Frei K; Ambar B; Adachi N; Yonekawa Y; Fontana A
J Neuroimmunol; 1998 Jul; 87(1-2):105-13. PubMed ID: 9670851
[TBL] [Abstract][Full Text] [Related]
15. Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack.
O'Connell J; Bennett MW; O'Sullivan GC; Collins JK; Shanahan F
Dis Esophagus; 1999; 12(2):83-9. PubMed ID: 10466039
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor-alpha and interferon-gamma induce expression of functional Fas ligand on HT29 and MCF7 adenocarcinoma cells.
Naujokat C; Sezer O; Possinger K
Biochem Biophys Res Commun; 1999 Nov; 264(3):813-9. PubMed ID: 10544014
[TBL] [Abstract][Full Text] [Related]
17. Killing of Fas ligand-resistant renal carcioma cells by interleukin-2- and BCG-activated effector cells.
Brandau S; Suttmann H; Flad HD; Jocham D; Böhle A
Cancer Immunol Immunother; 2000 Sep; 49(7):369-76. PubMed ID: 10999463
[TBL] [Abstract][Full Text] [Related]
18. IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity In vivo.
Aung S; Graham BS
J Immunol; 2000 Apr; 164(7):3487-93. PubMed ID: 10725701
[TBL] [Abstract][Full Text] [Related]
19. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.
O'Connell J; O'Sullivan GC; Collins JK; Shanahan F
J Exp Med; 1996 Sep; 184(3):1075-82. PubMed ID: 9064324
[TBL] [Abstract][Full Text] [Related]
20. Expression of Fas and Fas ligand and apoptosis in tumor-associated lymphocytes and in tumor cells from malignant pleural effusions.
Sikora J; Dworacki G; Zeromski J
Nat Immun; 1998; 16(5-6):244-55. PubMed ID: 11061592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]